Abstract

The relative superiority of atezolizumab-bevacizumab versus pembrolizumab-lenvatinib in treatment of unresectable hepatocellular carcinoma (HCC) remains uncertain. This study aims to compare the efficacy of atezolizumab-bevacizumab and pembrolizumab-lenvatinib in first-line treatments for unresectable HCC.